Although a PLGA formulation capable of releasing the drug over several months is theoretically possible, the exenatide formulation, marketed as Exenatide QW (Bydureon) by AstraZeneca, was limited to a once-weekly injection
Committee ASoP, Gan SI, Rajan E, Adler DG, Baron TH, Anderson MA, Cash BD, Davila RE, Dominitz JA, Harrison ME 3rd, Ikenberry SO, Lichtenstein D, Qureshi W, Shen B, Zuckerman M, Fanelli RD, Lee KK, Van Guilder T (2007) Role of EUS
2, demonstrated a progressive increase in ADR reporting beginning in 2005, reaching peak levels in 2007, and subsequently stabilizing after 2015
But on the bright side, studies on GLP-1s show that these symptoms are often temporary
Hello everyone, Today I want to share a news that has made me reflect as a person with type 1 diabetes for more than 25 years.This is the worrying increase in the use of GLP-1 medications (such as Ozempic or Zepbound) between people with type 1 diabetes, especially those with obesity
Savage DC